Contents

Glossary

• 1.7 Procedural matters
• 1.8 NDPSC Working Parties
  • 1.8.1 Codeine Working Party including codeine combinations & definition of "compounded"
• 1.9 Proposed routine changes to the SUSDP

2. Proposed changes/additions to Parts 1 to 3 and Part 5 of the Standard for the Uniform Scheduling of Drugs and Poisons

• 2.1 SUSDP, Part 1
  • 2.1.1 Interpretation of aerosol concentration in the SUSDP
  • 2.1.2 Review of references in the SUSDP
• 2.2 SUSDP, Part 2
• 2.3 SUSDP, Part 3
  • 2.3.1 Schedules 5 & 6 storage statements
• 2.4 SUSDP, Part 5
  • 2.4.1 Appendix A - Leaching of Poisons

Top of page

Agricultural/veterinary, industrial and domestic chemicals

3. Matters arising from the minutes of the previous meeting

• 3.1 Methyldibromo glutaronitrile (MDBGN)
• 3.2 Cyanogen (Ethanedinitrile)

4. Other outstanding matters from previous meetings

• 4.1 Lead in paints or tinters
• 4.2 Prothioconazole
• 4.3 Overlap between Appendix C and the Schedules
• 4.4 2,4-D

5. Proposed changes/additions to the Standard for the Uniform Scheduling of Drugs and Poisons

• 5.1 SUSDP, Part 4
  • 5.1.1 Pyrithione Zinc
• 5.2 SUSDP, Part 5

6. Matters referred by the Australian Pesticides and Veterinary Medicines Authority (APVMA)

• 6.1 Benomyl
• 6.2 Didecyldimethylammonium carbonate / bicarbonate

7. Matters referred by Office of Chemical Safety (OCS) or the National Industrial Chemicals Notification and Assessment Scheme (NICNAS)

8. Other matters for consideration

9. Information items (Ag/vet, industrial & domestic chemicals)

Top of page

Pharmaceuticals

10. Matters arising from the minutes of the previous meeting

11. Other outstanding matters from previous meetings

• 11.1 Atropine
• 11.2 Hydroquinone

12. Proposed changes/additions to the Standard for the Uniform Scheduling of Drugs and Poisons

• 12.1 SUSDP, Part 4
  • 12.1.1 Lignocaine
  • 12.1.2 Ketotifen
  • 12.1.3 Electronic cigarettes containing nicotine
• 12.2 SUSDP, Part 5
  • 12.2.1 Isotretinoin

13. Matters referred by the registration process for prescription medicines

• 13.1 New substances (not seen before by NDPSC)
  • 13.1.1 Anidulafungin
  • 13.1.2 Desvenlafaxine
  • 13.1.3 Romiplostim
  • 13.1.4 H5N1 influenza virus haemagglutinin
  • 13.1.5 Rabbit anti-human thymocyte immunoglobulin
• 13.2 For information (substances already scheduled)
  • 13.2.1 Aliskiren

14. Other matters for consideration

15. Matters referred by the Medicines Evaluation Committee (MEC)

16. Matters referred by the Medicines Classification Committee (MCC) of New Zealand

• 16.1 Medicines for harmonisation
• 16.2 Harmonisation of medicines
  • 16.2.1 Iron

17. Minutes of the Adverse Drug Reactions Advisory Committee (ADRAC)

18. Minutes of the Medical Device Evaluation Committee (MDEC)

19. Information items

20. Gazettal notices

21. Amendments to the SUSDP

• 21.1 Editorial changes and errata
  • 21.1.1 2-Octyl-4-isothiazolin-3-one (Octhilinone)
  • 21.1.2 SUSDP Part 2, Subparagraph 16(1)(b)
  • 21.1.3 Doxylamine
  • 21.1.4 Piper Methysticum (Kava)
  • 21.1.5 Fluorides
  • 21.1.6 Bifonazole
  • 21.1.7 Boron
  • 21.1.8 Tetrachlorvinphos
  • 21.1.9 Methomyl
  • 21.1.10 Morantel
  • 21.1.11 Picric Acid
  • 21.1.12 Lenalidomide
• 21.2 SUSDP amendment